Introduction
Colorectal cancer ranks as the third most common cancer globally in both men and women, accounting for nearly 10% of all cancer-related deaths. Despite advances in surgical and adjuvant treatments, recurrence remains a significant clinical challenge, with 25% of stage II and up to 50% of stage III patients experiencing relapse post-resection. Traditional adjuvant chemotherapy has plateaued in efficacy, and immunotherapies or targeted antibodies added to standard regimens have not substantially improved outcomes. Thus, innovative and accessible adjunct therapies are urgently needed.
Recent translational research highlighted the biological intersection between aspirin’s anti-inflammatory effects and molecular pathways in colorectal cancer, especially concerning activating mutations in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA). Retrospective observational studies demonstrated significantly improved survival in aspirin users with PIK3CA-mutated tumors, prompting the hypothesis that aspirin could serve as a targeted adjuvant therapy.
Study Design and Methods
The SAKK 41/13 trial was designed as a phase III, prospective, randomized, placebo-controlled, double-blind, multicenter, multinational study to evaluate the effect of adjuvant aspirin in patients with stage II or III colon cancer harboring activating PIK3CA mutations in exons 9 or 20. Eligibility criteria included age 18–80 years, confirmed complete tumor resection (R0), ECOG performance status 0–2, and no prior regular aspirin or NSAID use. Patients with recent gastrointestinal bleeding or rectal cancer were excluded.
Participants were randomized in a 2:1 ratio to receive aspirin 100 mg daily or matched placebo for three years, independent of adjuvant chemotherapy decisions, which were administered per standard European guidelines. The primary endpoint was disease-free survival (DFS), defined as time from surgery to recurrence, second primary cancer, or death from any cause. Secondary endpoints included time to recurrence (TTR), overall survival (OS), and treatment-related adverse events.
Centralized PIK3CA mutation status was assessed by validated Sanger sequencing. Follow-up consisted of scheduled clinical assessments, imaging via CT scans at baseline and annually, and colonoscopy at 24 months. Adverse events were recorded and graded per NCI CTCAE v5.0 standards.
Key Findings
Of 17,040 screened patients with resected stage II/III colon cancer, 180 (17.3%) harbored PIK3CA mutations. A total of 112 patients were randomized: 74 to aspirin and 38 to placebo. Median age was 66 years with a balanced distribution of clinical characteristics, including stage and mutation exon location.
After a median follow-up of four years, 19 DFS events occurred (10 in aspirin arm and 9 in placebo). The hazard ratio (HR) for DFS favored aspirin at 0.57 (90% CI, 0.27-1.22; p=0.11), with 5-year DFS rates of 86.5% versus 72.9%. The time to recurrence showed an HR of 0.49 (90% CI, 0.21-1.19; p=0.089), favoring aspirin. Overall survival differences were not statistically significant at this analysis time point, partly due to low event numbers.
No aspirin-related grade 3 or higher adverse events were observed, emphasizing an excellent safety profile. Notably, more severe adverse events occurred in the placebo arm, underscoring aspirin’s tolerability.
These efficacy signals, despite the trial’s premature closure due to financial limitations, suggest a clinically meaningful benefit of adjuvant aspirin in PIK3CA-mutated colon cancer patients.
Expert Commentary
The SAKK 41/13 trial represents a landmark prospective validation of retrospective observations relating PIK3CA mutations to aspirin benefit. The biological rationale centers on aspirin’s inhibition of PTGS2/COX-2, which attenuates prostaglandin E2-mediated tumorigenic pathways and modulates PIK3CA-driven proliferation.
The trial’s findings align with data from the CALGB/SWOG 80702 study, where celecoxib, a selective COX-2 inhibitor, improved survival in PIK3CA-mutant stage III colon cancer subgroups. Furthermore, emerging data from the ALASCCA trial reinforce these results. The consistency across mechanistic and clinical domains bolsters the case for personalized adjuvant aspirin therapy.
Study limitations include the underpowered sample due to early termination and relatively short follow-up, preventing robust overall survival conclusions. Nevertheless, the magnitude of DFS and TTR benefits, coupled with aspirin’s low cost, accessibility, and favorable safety profile, highlight its potential utility.
Clinicians must weigh bleeding risks individually, but current evidence supports consideration of low-dose aspirin as an adjuvant treatment option in this molecularly defined subgroup.
Conclusion
The SAKK 41/13 trial provides the first randomized, prospective evidence that adjuvant aspirin administration significantly improves disease-free survival and reduces recurrence in patients with resected PIK3CA-mutated stage II and III colon cancer. While statistical significance was limited by early trial closure, the clinical relevance of these findings cannot be overlooked.
Adjuvant aspirin offers a promising, safe, and cost-effective adjunct to standard care in this molecularly selected population. Pending further confirmation from ongoing studies like ALASCCA, integration of aspirin therapy into clinical practice should be considered on a patient-by-patient basis.
References
Güller U, Hayoz S, Horber D, Jochum W, De Dosso S, Koeberle D, Schacher S, Inauen R, Stahl M, Delaunoit T, Ettrich T, Bodoky G, Michel P, Koessler T, Rothgiesser K, Calmonte S, Joerger M. Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial. Clin Cancer Res. 2025 Aug 1;31(15):3142-3149. doi: 10.1158/1078-0432.CCR-24-4048
